CD274 and neoplasm: Here, the baseline PD-L1 expression was scored by immunohistochemistry in tumor cells (as the percentage of PD-L1 expressing tumor cells TC3 (≥50%), TC2 (≥5% and <50%), TC1 (≥1% and < 5%), and TC0 (<1%)) and tumor-infiltrating immune cells (as the percentage of tumor area: IC3 (≥10%), IC2 (≥5% and <10%), IC1 (≥1% and <5%), and IC0 (<1%)).